glp-1 and gip receptor agonist Dual GIP/GLP-1 agonists: New advances for treating type-2 diabetes Frontiers | The evolution of

This enhancement is demonstrable through an increase in mitochondrial DNA content, the upregulation of genes integral to mitochondrial biogenesis, and the increased expression of proteins pivotal in oxidative phosphorylation

Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus

GLP-1 RAs mimic this effect by enhancing glucose-dependent insulin secretion, inhibiting glucagon, delaying gastric emptying, and reducing appetite mechanisms that can improve glycemic control and support weight loss [1]

This is conferred by a targeted amino acid substitution at the 8th position, replacing alanine with glutamic acid, a modification also found in exenatide-based GLP-1 therapies

These views are not necessarily endorsed or verified by the National Academy of Medicine or the National Academies of Sciences, Engineering, and Medicine and should not be construed as reflecting any group consensus